MedPricer as Infrastructure: Why the Dataset Is More Valuable Than the Interface
Drug pricing data is not scarce. CMS publishes ASP quarterly. State Medicaid agencies report NADAC weekly. WAC is commercially available ...
NADAC and the Invisible Squeeze on Independent Pharmacies
The consolidation of American pharmacy has been documented in aggregate—chains absorbing independents, mail-order displacing retail, PBM-owned pharmacies growing at the ...
ASP as a Lagging Indicator: What MedPricer’s Dataset Reveals About Rebate Timing
Average sales price data arrives six months after the fact. CMS calculates it based on manufacturer-reported sales and rebates from ...
The Price Nobody Pays: How WAC Became the Most Quoted Fiction in Drug Markets
List prices in pharmaceuticals are less prices than they are political objects—numbers that exist to be negotiated away, invoiced and ...
Hormonal Architecture: The Economic and Clinical Logic of Multi-Axis Peptide Protocols
Endocrinology has always contained a quiet paradox. The more precisely physicians attempt to control hormonal systems, the more unpredictable those ...
Endocrine Stacking: The Emerging Logic Behind Sermorelin, Pregnenolone, and Enclomiphene
The most interesting developments in endocrine medicine rarely arrive as new drugs. They arrive as new combinations. In small metabolic ...
Stacked Signals: What Semaglutide and Sermorelin Reveal About the Future of Metabolic Protocols
The metabolic‑drug boom created a seductive narrative: pharmacology had finally solved obesity. Yet within clinical practice the story has already ...
Beyond Weight Loss: The Quiet Rise of Semaglutide–Sermorelin Peptide Stacking
The obesity‑drug revolution was supposed to be simple: one injection, one mechanism, one dramatic physiological outcome. But metabolic medicine rarely ...
Convenience Versus Precision: The Market Logic of Oral Semaglutide
Drug development traditionally rewards efficiency. Oral semaglutide quietly abandoned that principle. The injectable form of semaglutide achieves near‑complete systemic delivery. ...
A Fraction of a Percent: The Pharmacokinetic Puzzle of Oral Semaglutide
Semaglutide exists in two pharmaceutical realities at once. In one form it is nearly perfectly absorbed. In another it barely ...
The Molecule That Hates the Stomach: Semaglutide and the Strange Economics of Oral Bioavailability
The most expensive problem in modern metabolic medicine may not be obesity. It may be the human stomach. Semaglutide, the ...
Markets of Complexity: The Economic Consequences of Combined Peptide and Hormone Therapies
Complex physiology produces complicated markets. The rapid expansion of peptide medicine has intersected with another long-standing domain of endocrine care: ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more